Table 1. Patient characteristics according to number of adjuvant chemotherapy cycles.
| Characteristics | All (n = 237) | 4 Cycles (n = 67) | 6 Cycles (n = 105) | 8 Cycles (n = 65) |
| n (%) | n (%) | n (%) | n (%) | |
| Age at diagnosis (median, range) | 57 (30–76) | 58 (36–75) | 57 (30–73) | 54 (30–76) |
| <60 | 148 (62.4) | 34 (50.7) | 68 (64.8) | 46 (70.8) |
| ≥60 | 89 (37.5) | 33 (49.3) | 37(35.2) | 19 (29.2) |
| Gender | ||||
| Male | 172 (72.6) | 52 (77.6) | 72 (68.6) | 48 (73.8) |
| Female | 65 (27.4) | 15 (22.4) | 33 (31.4) | 17 (26.2) |
| Performance status (ECOG) | ||||
| 0 | 126 (53.2) | 36 (53.7) | 54 (51.4) | 36 (55.4) |
| 1 | 111 (46.8) | 31 (46.3) | 51 (48.6) | 29 (44.6) |
| Chemotherapy regimen | ||||
| FU monochemotheray | 24 (10.1) | 8 (11.9) | 8 (7.6) | 8 (12.3) |
| FU plus oxaliplatin | 145 (61.2) | 42 (62.7) | 69 (78.1) | 34 (52.3) |
| Other FU-based combinations | 68 (28.7) | 17 (28.4) | 28 (26.7) | 23 (35.4) |
| AJCC stage | ||||
| IB | 13 (5.5) | 4 (6.0) | 6 (5.7) | 3 (4.6) |
| II | 81 (34.2) | 23 (34.3) | 40 (38.1) | 18 (27.7) |
| IIIA | 43 (18.1) | 11 (16.4) | 18 (17.1) | 14 (21.5) |
| IIIB | 44 (18.6) | 11 (16.4) | 17 (16.2) | 16 (24.6) |
| IIIC | 56 (23.6) | 18 (26.9) | 24 (22.9) | 14 (21.5) |
| Tumor classification | ||||
| T1 | 9 (3.8) | 1 (1.5) | 7 (6.7) | 1 (1.5) |
| T2 | 32 (13.5) | 10 (14.9) | 13 (12.4) | 9 (13.8) |
| T3 | 49 (20.7) | 10 (14.9) | 22 (21.0) | 17 (26.2) |
| T4 | 147 (62.0) | 46 (68.7) | 63 (60.0) | 38 (58.5) |
| Nodal classification | ||||
| N0 | 64 (27.0) | 22 (32.8) | 25 (23.8) | 17 (26.2) |
| N1 | 52 (21.9) | 12 (17.9) | 28 (26.7) | 12 (18.5) |
| N2 | 59 (24.9) | 14 (20.9) | 26 (24.8) | 19 (29.2) |
| N3 | 62 (26.2) | 19 (28.4) | 26 (24.8) | 17 (26.2) |
| Histology grade | ||||
| G1–G2 | 72 (30.4) | 17 (25.4) | 31 (29.5) | 24 (36.9) |
| G3–G4 | 165 (69.6) | 50 (74.6) | 74 (70.5) | 41 (63.1) |
| Lymph node dissection | ||||
| D1 | 66 (27.8) | 15 (22.4) | 35 (33.3) | 16 (24.6) |
| D2 | 171 (72.2) | 52 (77.6) | 70 (66.7) | 49 (75.4) |
Abbreviations: ECOG, Eastern Cooperative Oncology Group; FU, fluorouracil; AJCC, American Joint Committee on Cancer; G1, well differentiated; G2, moderately differentiated; G3, poorly differentiated; G4, undifferentiated.